プロモーションスケジュール Clearside Biomedical, Inc.
詳細なスケジュール
簡易グラフ
会社について Clearside Biomedical, Inc.
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. さらに詳しく| IPO date | 2016-06-02 |
|---|---|
| ISIN | US1850631045 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://clearsidebio.com |
| Цена ао | 0.861 |
| 1日あたりの価格変動: | +3.33% (0.861) |
|---|---|
| 週ごとの価格変動: | -4.11% (0.9278) |
| 月ごとの料金変更: | -13.62% (1.03) |
| 3ヶ月間の価格変動: | -12.77% (1.02) |
| 半年間の価格変動: | -32.08% (1.31) |
| 年間の価格変動: | -47.97% (1.71) |
| 3年間の価格推移: | -34.1% (1.35) |
| 5年間の価格推移: | -64.69% (2.52) |
| 10年間の価格推移: | 0% (0.8897) |
| 年初からの価格変動: | +1.99% (0.8723) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Vanguard Group Inc | 2176316 | 2.91 |
| Carmignac Gestion | 2132744 | 2.85 |
| Blackrock Inc. | 759743 | 1.02 |
| Geode Capital Management, LLC | 490690 | 0.66 |
| Renaissance Technologies, LLC | 384689 | 0.51 |
| State Street Corporation | 193363 | 0.26 |
| Bridgeway Capital Management, Inc. | 175600 | 0.24 |
| First Manhattan Company | 175000 | 0.23 |
| Johnson & Johnson | 169629 | 0.23 |
| Morgan Stanley | 144434 | 0.19 |
| ETF | 共有, % | 年間の利益率, % | 配当金, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02367 | 17.09 | 1.54048 |
| 0.02 | 17.09 | 1.54 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, CEO & Director | 836.15k | 1952 (73 年) |
| Mr. Charles A. Deignan | Chief Financial Officer | 568.68k | 1964 (61 年) |
| Ms. Jenny R. Kobin | Head of Investor Relations | N/A | 1967 (58 年) |
| Mr. Rick McElheny | Senior Vice President of Corporate Development & Alliance Management | N/A | |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | N/A | 1965 (60 年) |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | N/A | |
| Mr. Leslie B. Zacks | Secretary | N/A | 1969 (56 年) |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer |
住所: United States, Alpharetta. GA, 900 North Point Parkway - Googleマップで開く, Yandexマップを開く
Webサイト: https://clearsidebio.com
Webサイト: https://clearsidebio.com
